First Page | Document Content | |
---|---|---|
![]() Date: 2010-10-05 09:53:16Finasteride Benign prostatic hyperplasia 5-alpha-reductase inhibitor Transurethral resection of the prostate Prostate cancer Urinary retention Testosterone Dihydrotestosterone Merck & Co. Medicine Lactams Androgens | Add to Reading List |
![]() | DEVELOPMENT OF PHARMACEUTICAL PRODUCTS UTILIZING EXTRUSION TECHNOLOGIES Graciela Terife Senior Scientist, Product Value Enhancement Merck & Co., Summit, NJDocID: 1nXt9 - View Document |
![]() | Title: font: times; size: 18 point; style: plain; justified: center; capitalization: first word and Names only THE CHALLENGE OF DEVELOPING AN MMRVVV COMBINATION VACCINE Alan R. Shaw, PhDDocID: 1gGkP - View Document |
![]() | Your contact News Release Gangolf SchrimpfDocID: 1aWSz - View Document |
![]() | TRUSOPT Ped data PARDocID: 1aNXe - View Document |
![]() | CNODES: A Canadian Initiative Samy Suissa Lady Davis Institute, Jewish General Hospital McGill University Montreal, CanadaDocID: 1aAtH - View Document |